硝苯地平联合不同剂量阿托伐他汀治疗多支血管病变冠心病合并高血压的安全性及对患者血压、炎性因子水平的影响分析  

The safety of nifedipine combined with different doses of atorvastatin in the treatment of multivessel disease coronary heart disease complicated with hypertension and its influence on blood pressure and inflammatory factor levels

作　　者：张都生[1] 许锦鸿[1] 陈威[1] 洪景宣 郭延松[1] ZHANG Du-sheng;XU Jin-hong;CHEN Wei(Internal Medicine-Cardiovascular Department,Fujian Medical University Provincial School of Clinical Medicine,Fujian Provincial Hospital,Fuzhou 350001,China)

机构地区：[1]福建医科大学省立临床医学院,福建省立医院心内科,350001

出　　处：《中国现代药物应用》2020年第23期4-7,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探究硝苯地平联合不同剂量阿托伐他汀治疗多支血管病变冠心病合并高血压的安全性与疗效,以及对患者血压、炎性因子水平的影响。方法 174例多支血管病变冠心病合并高血压患者,根据治疗药物不同分为对照组和观察组,各87例。对照组采用硝苯地平控释片联合20 mg/d阿托伐他汀治疗,观察组采用硝苯地平控释片联合40 mg/d阿托伐他汀治疗。对比两组患者的治疗效果、血压水平、炎性因子水平和不良反应发生情况。结果观察组治疗总有效率为93.10%,高于对照组的72.41%,差异具有统计学意义(P<0.05);两组不良反应发生率对比差异无统计学意义(P>0.05)。治疗后,两组收缩压、舒张压对比差异无统计学意义(P>0.05)。治疗后,观察组白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)和肿瘤坏死因子-α(TNF-α)水平分别为(3.18±0.85)pg/ml、(5.23±0.63)mg/L、(34.18±4.23)pg/ml,显著低于对照组的(6.26±0.76)pg/ml、(6.89±0.74)mg/L、(41.40±5.61)pg/ml,差异具有统计学意义(P<0.05)。结论硝苯地平联合40 mg/d阿托伐他汀治疗多支血管病变冠心病合并高血压患者,不仅能维持良好的降压作用,更好地改善心绞痛症状,还能降低炎性因子水平,且未增加不良反应,值得临床推广应用。Objective To investigate the safety and efficacy of nifedipine combined with different doses of atorvastatin in the treatment of multivessel disease coronary heart disease complicated with hypertension and its influence on blood pressure and inflammatory factor levels.Methods A total of 174 cases of multivessel disease coronary heart disease complicated with hypertension were divided into control group and observation group according to different treatment drugs,with 87 cases in each group.The control group was treated with nifedipine controlled-release tablets combined with atorvastatin 20 mg/d,while the observation group was treated with nifedipine controlled-release tablets combined with atorvastatin 40 mg/d.The therapeutic effect,blood pressure,inflammatory factors and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment of the observation group was 93.10%,which was higher than 72.41%of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05).After treatment,there was no statistically significant difference in systolic blood pressure and diastolic blood pressure between the two groups(P>0.05).After treatment,the interleukin-6(IL-6),high sensitivity C-reactive protein(hs-CRP)and tumor necrosis factor-α(TNF-α)of the observation group were(3.18±0.85)pg/ml,(5.23±0.63)mg/L and(34.18±4.23)pg/ml,which were significantly lower than(6.26±0.76)pg/ml,(6.89±0.74)mg/L and(41.40±5.61)pg/ml of the control group,and the difference was statistically significant(P<0.05).Conclusion For patients with multivessel disease coronary heart disease complicated with hypertension,nifedipine combined with atorvastatin 40 mg/d can not only maintain good antihypertensive effect,but also improve the symptoms of angina pectoris,and reduce the level of inflammatory factors without increasing adverse reactions,which is worthy of clinical promot

关 键 词：冠心病 高血压 硝苯地平控释片 阿托伐他汀 炎性因子水平 

分 类 号：R541.4[医药卫生—心血管疾病] R544.1[医药卫生—内科学]